Table 2.

Cost-effectiveness results (discounted).

Treatment	Mean life-years* (95% CI)	Mean QALYs* (95% CI)	Mean costs,* $ (95% CI)	ICER, $/QALY
ADT alone	4.42 (4.25–4.59)	3.38 (3.24– 3.52)	391 976 (343172–442 455)	NA
Enzalutamide plus ADT	4.96 (3.04–8.19)	3.92 (2.41–6.34)	596 620 (351 169–1 090 043)	Dominated†
Docetaxel plus ADT	5.11 (4.68–5.58)	3.92 (3.60–4.27)	414693 (327 800–505 878)	42 069 (vs ADT alone)
Abiraterone acetate plus ADT	6.06 (5.43–6.78)	4.76 (4.29–5.29)	464097 (326 833–646 606)	58 814 (vs docetaxel plus ADT)
Apalutamide plus ADT	6.53 (4.65–8.88)	5.01 (3.64–6.70)	959 016 (673 017–1 311 560)	1 979 676 (vs abiraterone acetate plus ADT)

ADT indicates androgen deprivation therapy; CI, confidence interval, ICER, incremental cost-effectiveness ratio, NA, not applicable; QALY, quality-adjusted life-year.

^*Life-years, QALYs, and costs were discounted at an annual rate of 3% to reflect present value. Costs were in 2020 US dollars.

^†Enzalutamide plus ADT was dominated by docetaxel plus ADT, given that it resulted in higher costs for the same QALYs.